ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
US-2017247447-A1 · Aug 31, 2017 · US
Anti-PDGF-B antibodies and methods of use
US10087246B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10087246-B2 |
| Application number | US-201715590172-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 9, 2017 |
| Priority date | Nov 10, 2014 |
| Publication date | Oct 2, 2018 |
| Grant date | Oct 2, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
First claim
Opening claim text (preview).
What is claimed is: 1. An antibody that specifically binds to human PDGF-B, wherein the antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 93, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 94, (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 96, (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 98, (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 99, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 100. 2. The antibody of claim 1 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:92 and a variable light chain comprising the amino acid sequence of SEQ ID NO:97. 3. The antibody of claim 1 or claim 2 , wherein the antibody is of the human subclass IgG1 or the human subclass IgG4. 4. The antibody of claim 1 or claim 2 , wherein the antibody blocks the biological activity of human PDGF-B by inhibiting the binding of human PDGF-B to human PDGF receptor. 5. A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier. 6. A pharmaceutical formulation comprising the antibody of claim 2 and a pharmaceutically acceptable carrier. 7. The pharmaceutical formulation of claim 5 or claim 6 , further comprising an additional therapeutic agent selected from an anti-ANG2 antibody and an anti-VEGF antibody. 8. An antibody that specifically binds to human PDGF-B, wherein the antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 102, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 103, (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 105, (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 107, (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 108, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 109. 9. The antibody of claim 8 , wherein the antibody comprises a variable heavy chain comprising the amino acid sequence of SEQ ID NO:101 and a variable light chain comprising the amino acid sequence of SEQ ID NO:106. 10. The antibody of claim 8 or 9 , wherein the antibody is of the human subclass IgG1 or the human subclass IgG4. 11. The antibody of claim 8 or claim 9 , wherein the antibody blocks the biological activity of human PDGF-B by inhibiting the binding of human PDGF-B to human PDGF receptor. 12. A pharmaceutical formulation comprising the antibody of claim 8 and a pharmaceutically acceptable carrier. 13. A pharmaceutical formulation comprising the antibody of claim 9 and a pharmaceutically acceptable carrier. 14. The pharmaceutical formulation of claim 12 or claim 13 , further comprising an additional therapeutic agent selected from an anti-ANG2 antibody and an anti-VEGF antibody.
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Ophthalmic agents · CPC title
variable (Fv) region, i.e. VH and/or VL · CPC title
Valency · CPC title
Fab or Fab' · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10087246B2 cover?
- Herein are reported anti-PDGF-B antibodies and their use in ophthalmology.
- Who is the assignee on this patent?
- Hoffmann La Roche
- What technology area does this patent fall under?
- Primary CPC classification C07K16/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).